William R. Hiatt, MD, on the Practice-Guiding Results of a VOYAGER-PAD Subgroup Analysis
A new subgroup analysis of the VOYAGER-PAD trial revealed whether adding clopidogrel to the rivaroxaban and aspirin regime of a patient with peripheral artery disease (PAD) at the time of revascularization is beneficial. In this podcast, William R. Hiatt, MD, provides insight into the analysis results.\n\nThe topic is one he presented about during a late-breaking clinical trial session, \u201cThe Benefit and Risk of Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease After Lower Extremity Revascularization (LER) With and Without Concomitant Clopidogrel: a Key Subgroup Analysis From VOYAGER-PAD,\u201d at ACC.20/WCC Virtual. For more, click here: www.consultant360.com/cardiology